Positive Effects of Haematococcus Astaxanthin on Oxidative Stress and Lipid Profile in Overweight and Obese Adults

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01167205

Enrollment

Registered

2010-07-22

Start date

2010-08-31

Completion date

2011-03-31

Last updated

2010-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Overweight, Obesity

Keywords

Healthy adults with BMI over 25.0 kg/m2

Brief summary

The purpose of this study is to determine whether astaxanthin (ASX) supplementation will reduce obesity-induced oxidative stress and improve lipid profile in overweight and obese adults.

Interventions

DIETARY_SUPPLEMENTastaxanthin

astaxanthin 20mg for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects with BMI over 25.0 kg/m2 * Non-smoker

Exclusion criteria

* Excessive alcohol consumption * Pregnant or lactating women * Dyslipidemia, hyperglycemia, or other chronic diseases. * Subjects who were taking vitamin supplements

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of the plasma MDA (malonaldehyde) level	12 weeks	MDA is a three chain aldehyde produced during the composition of a lipid hydroperoxide and is a well known indicator of lipid peroxidation. The purpose of this stduy is to determine whether ASX supplementation lowers oxidative stress using MDA,a biomarker.

Countries

South Korea

Contacts

Primary ContactYeo-kyu Youn, Doctor

ykyoun@snu.ac.kr+82 2 2072 3447

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026